\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ unremarkable\\.laboratory\\ significant\\ for\\ hct\\ of\\ 21\\.\\ \\ \\ endoscopy\\ revealed\\ a\\ 2\\-3\\ cm\\ ulcerated\\ mass\\ at\\ the\\ gatroesophageal\\ junction\ \(0\)\
\-\ this\\ patient\\ will\\ initially\\ receive\\ adjuvant\\ chemotherapy\\ \\ \\(5\\-\\ fluorouracil\\ \\)\\ and\\ radiotherapy\\.\\ \\ she\\ will\\ then\\ undergo\\ surgical\\ resection\\ of\\ her\\ tumor\\ followed\\ by\\ additional\\ adjuvant\\ chemotherapy\\ and\\ radiotherapy\\ to\\ prevent\\ recurrence\\.\ \(0\)\
\-\ ct\\ of\\ chest\\,\\ abdomen\\,\\ and\\ pelvis\\ with\\ contrast\\-\\ \\ lobular\\ thickening\\ of\\ the\\ lower\\ esophageal\\ wall\\ and\\ luminal\\ wall\\ at\\ the\\ ge\\ junction\\;\\ no\\ adenopathypet\\-\\ no\\ abnormal\\ findingsesophageal\\ us\\-t2\\/t3\ \(0\)\
\-\ adenocarcinoma\\ of\\ the\\ gastroesophageal\\ junction\\,\\ no\\ evidence\\ of\\ barrett\\ esophagus\\ found\\ \\-\\ stage\\:\\ t3n0m0\ \(0\)\
\-\ malignancy\\,\\ leiomyoma\\ or\\ benign\\ tumor\\,\\ irritation\\,\\ inflammation\ \(0\)\
\-\ the\\ patient\\ is\\ a\\ 39\\ year\\ old\\ female\\ with\\ a\\ chief\\ complaint\\ of\\ worsening\\ solid\\ and\\ liquid\\ dysphagia\\ over\\ a\\ \\>6\\ months\\ duration\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adjuvant\\:\\ 0\\.08480705141641752\ \(0\)\
\-\ junction\\:\\ 0\\.07953503246970109\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.07710519276032998\ \(0\)\
\-\ unremarkable\\.laboratory\\:\\ 0\\.06530013647382592\ \(0\)\
\-\ fluorouracil\\:\\ 0\\.06530013647382592\ \(0\)\
\-\ adenopathypet\\-\\:\\ 0\\.06530013647382592\ \(0\)\
\-\ findingsesophageal\\:\\ 0\\.06530013647382592\ \(0\)\
\-\ us\\-t2\\/t3\\:\\ 0\\.06530013647382592\ \(0\)\
\-\ t3n0m0\\:\\ 0\\.06530013647382592\ \(0\)\
\-\ gatroesophageal\\:\\ 0\\.060165712914122614\ \(0\)\
\-\ 5\\-\\:\\ 0\\.060165712914122614\ \(0\)\
\-\ contrast\\-\\:\\ 0\\.05716226766887695\ \(0\)\
\-\ 21\\.\\:\\ 0\\.04824395059979594\ \(0\)\
\-\ barrett\\:\\ 0\\.04824395059979594\ \(0\)\
\-\ ulcerated\\:\\ 0\\.046893420549470356\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.04537697459467949\ \(0\)\
\-\ liquid\\:\\ 0\\.044313370962298385\ \(0\)\
\-\ ge\\:\\ 0\\.04348947736888932\ \(0\)\
\-\ irritation\\:\\ 0\\.04274811841661537\ \(0\)\
\-\ luminal\\:\\ 0\\.04207425339286925\ \(0\)\
\-\ will\\:\\ 0\\.03960712619820951\ \(0\)\
\-\ gastroesophageal\\:\\ 0\\.03855259638016499\ \(0\)\
\-\ chief\\:\\ 0\\.03743939487609582\ \(0\)\
\-\ receive\\:\\ 0\\.037269102148505456\ \(0\)\
\-\ leiomyoma\\:\\ 0\\.037269102148505456\ \(0\)\
\-\ wall\\:\\ 0\\.036669024003536985\ \(0\)\
\-\ endoscopy\\:\\ 0\\.03662457343006376\ \(0\)\
\-\ lobular\\:\\ 0\\.03575210649927573\ \(0\)\
\-\ hct\\:\\ 0\\.034378749289413785\ \(0\)\
\-\ 2\\-3\\:\\ 0\\.03415426521907802\ \(0\)\
\-\ duration\\:\\ 0\\.03351895542828228\ \(0\)\
\-\ undergo\\:\\ 0\\.03213467858880216\ \(0\)\
\-\ prevent\\:\\ 0\\.031413388484911965\ \(0\)\
\-\ dysphagia\\:\\ 0\\.030826356102288708\ \(0\)\
\-\ tumor\\:\\ 0\\.029514552616456465\ \(0\)\
\-\ 39\\:\\ 0\\.02941726916672524\ \(0\)\
\-\ complaint\\:\\ 0\\.029244325729710488\ \(0\)\
\-\ esophageal\\:\\ 0\\.02901984165937472\ \(0\)\
\-\ recurrence\\:\\ 0\\.027614237694326773\ \(0\)\
\-\ esophagus\\:\\ 0\\.027478318148636428\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.027344847737505475\ \(0\)\
\-\ stage\\:\\ 0\\.027000255029098863\ \(0\)\
\-\ inflammation\\:\\ 0\\.02691655461981047\ \(0\)\
\-\ initially\\:\\ 0\\.02576281736492726\ \(0\)\
\-\ additional\\:\\ 0\\.025381086623333316\ \(0\)\
\-\ solid\\:\\ 0\\.025247012240787996\ \(0\)\
\-\ worsening\\:\\ 0\\.024922073854820724\ \(0\)\
\-\ malignancy\\:\\ 0\\.024459923539270487\ \(0\)\
\-\ pelvis\\:\\ 0\\.023000677085863917\ \(0\)\
\-\ then\\:\\ 0\\.02252568058090437\ \(0\)\
\-\ benign\\:\\ 0\\.02184481753357927\ \(0\)\
\-\ thickening\\:\\ 0\\.02145647829402483\ \(0\)\
\-\ followed\\:\\ 0\\.021221302750953863\ \(0\)\
\-\ \\>\\:\\ 0\\.021030870479026405\ \(0\)\
\-\ revealed\\:\\ 0\\.020314621406415507\ \(0\)\
\-\ found\\:\\ 0\\.019948337884830462\ \(0\)\
\-\ resection\\:\\ 0\\.019740115966816435\ \(0\)\
\-\ no\\:\\ 0\\.019120981126751157\ \(0\)\
\-\ her\\:\\ 0\\.019032678951740264\ \(0\)\
\-\ 6\\:\\ 0\\.018904593787962033\ \(0\)\
\-\ abdomen\\:\\ 0\\.018750994539968122\ \(0\)\
\-\ abnormal\\:\\ 0\\.018052535113443787\ \(0\)\
\-\ she\\:\\ 0\\.01776878623299387\ \(0\)\
\-\ months\\:\\ 0\\.01728845403474124\ \(0\)\
\-\ at\\:\\ 0\\.017152046708616787\ \(0\)\
\-\ significant\\:\\ 0\\.01702109000780906\ \(0\)\
\-\ cm\\:\\ 0\\.016977452724570265\ \(0\)\
\-\ evidence\\:\\ 0\\.0165958709879028\ \(0\)\
\-\ over\\:\\ 0\\.016115871038073798\ \(0\)\
\-\ physical\\:\\ 0\\.01552966866356473\ \(0\)\
\-\ chest\\:\\ 0\\.015146140741166806\ \(0\)\
\-\ \\;\\:\\ 0\\.015003119914463658\ \(0\)\
\-\ lower\\:\\ 0\\.014236015328621204\ \(0\)\
\-\ exam\\:\\ 0\\.013905436592218802\ \(0\)\
\-\ \\-\\:\\ 0\\.013568358953395285\ \(0\)\
\-\ surgical\\:\\ 0\\.013305346446307063\ \(0\)\
\-\ female\\:\\ 0\\.013013039047761731\ \(0\)\
\-\ patient\\:\\ 0\\.012690250828390934\ \(0\)\
\-\ \\,\\:\\ 0\\.012031558467434995\ \(0\)\
\-\ a\\:\\ 0\\.011751105239069668\ \(0\)\
\-\ by\\:\\ 0\\.010539784468480555\ \(0\)\
\-\ ct\\:\\ 0\\.008854101136237356\ \(0\)\
\-\ mass\\:\\ 0\\.008803414866278256\ \(0\)\
\-\ \\:\\:\\ 0\\.008372406044375297\ \(0\)\
\-\ or\\:\\ 0\\.007418687029360797\ \(0\)\
\-\ this\\:\\ 0\\.0071195349134380225\ \(0\)\
\-\ year\\:\\ 0\\.0070822612538734425\ \(0\)\
\-\ and\\:\\ 0\\.006667000212304387\ \(0\)\
\-\ old\\:\\ 0\\.006480997013794479\ \(0\)\
\-\ of\\:\\ 0\\.006040937819154955\ \(0\)\
\-\ for\\:\\ 0\\.005400801101057149\ \(0\)\
\-\ \\(\\:\\ 0\\.0053508276018063745\ \(0\)\
\-\ \\)\\:\\ 0\\.0052854643860244825\ \(0\)\
\-\ the\\:\\ 0\\.005120343877912066\ \(0\)\
\-\ is\\:\\ 0\\.004165116876923894\ \(0\)\
\-\ to\\:\\ 0\\.0031634674699480463\ \(0\)\
\-\ with\\:\\ 0\\.0017333952013316998\ \(0\)\
\-\ \\.\\:\\ 0\\.0007888785799410284\ \(0\)\
